News

Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Therapies for Autoimmune Diseases

Sonoma Biotherapeutics is to receive $75 million upfront, inclusive of $45 million cash and $30 million equity investment; with the potential for an additional $45 million development milestone payment. Sonoma Bio was founded by Jeff Bluestone, PhD, and Qizhi Tang, PhD, both UCSF researchers.

Exai Bio and Quantum Leap Healthcare Collaborative Announce Expanded Participation in I-SPY 2 Trial to Advance Exai’s Novel RNA-based Liquid Biopsy Platform in Breast Cancer

The expanded agreement is based on positive initial data using Exai’s platform in the trial, which demonstrated that oncRNAs were a significant predictor of patient outcomes.

UCSF Speakers Reach Record Numbers at 2023 Precision Medicine World Conference

UC San Francisco scientists, experts and thought leaders participated in 32 presentations and panels over the 3-day Precision Medicine World Conference (PMWC) held January 25-27, 2023. The forum drew more than 2,000 people from around the world from various sectors to foster collaboration, expand...

ClearPoint Neuro Announces Exclusive Multi-Year Licensing Agreement with UCSF for Innovative Intra-Cerebral Cellular Delivery Platform

ClearPoint Neuro, a global therapy-enabling platform company providing navigation and delivery to the brain, today announced an exclusive multi-year licensing agreement of intellectual property from UC San Francisco (UCSF) through its Innovation Ventures group to develop and commercialize a...

EpiBiologics Launches with $50 million to Advance Next-Generation Protein Degradation Platform

EpiBiologics, a biotechnology company building a next-generation antibody-based protein degradation platform for membrane and extracellular drug targets, launched today with $50 million in Series A funding.

MindRhythm's EPISODE-PS Initial Trial Results are Published

MindRhythm Inc, in partnership with Wayne State University School of Medicine in Detroit, Michigan, today announces the first publication of results from the hEadPulse for Ischemic StrOke DEtection Prehospital Study (EPISODE-PS) trial. MyndRhythm Inc., was co-founded by UCSF researcher Dr. Wade...

Thymmune Secures $7M in Seed Financing to Develop Thymus Cell Therapy Platform for Immune System Renewal

Thymmune Therapeutics, a biotechnology company developing scalable thymic cell therapies to restore immune function in aging and disease, announced today that it has secured $7 million in seed financing. We congratulate the UCSF researchers, Matthias Hebrok, Mark Anderson, and Audrey Parent, on...

Nested Therapeutics Announces Nomination of First Development Candidate, a Potential First-in-Class Inhibitor of the RAS/MAPK Pathway

Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers that were founded on the technology discovered by University researcher Kevan Shokat, PhD, today announced the nomination of the company’s first drug development...

Chroma Medicine Secures $135M in Series B Financing

Chroma, a genomic medicine company pioneering single-dose epigenetic editing therapeutics founded on UCSF research discovered by Luke Gilbert, PhD, and Jonathan Weissman, PhD., today announced the completion of a $135 million Series B financing. The financing will support the advancement of Chroma'...

MindRhythm Initiates Pivotal Portion of Prehospital Stroke Trial

MindRhythm in partnership with Wayne State University School of Medicine in Detroit, Michigan, today announces the conclusion of phase I and initiation of the pivotal portion of its hEadPulse for Ischemic StrOke DEtection Prehospital Study (EPISODE-VS). MindRhythm was co-founded by UCSFs Dr. Wade...